MedTrace Logo

Ultrasound Guided Botulinum Toxin Type A Injection of Subacromial-Subdeltoid Bursa in Hemiplegic Shoulder Pain

NCT04467450 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2020-10-08

No results posted yet for this study

Summary

Good shoulder function is a prerequisite for effective hand function, as well as for performing multiple tasks involving mobility, ambulation, and activities of daily living (ADL). A common sequela of stroke is hemiplegic shoulder pain, which can hamper functional recovery and subsequently lead to disability. Hemiplegic shoulder pain can begin as early as 2 weeks post stroke but typically occurs within 2-3 months post stroke.

Conditions

  • Subacromial Bursitis
  • Subdeltoid Bursitis

Interventions

DRUG

botulinum toxin type A

ultrasound guided injection of the botulinum toxin type A in the inflamed subacromial subdeltoid bursa

DRUG

Methyl Prednisolonate

ultrasound guided injection of Methyl Prednisolonate in the inflamed subacromial subdeltoid bursa

Sponsors & Collaborators

  • Benha University

    lead OTHER

Principal Investigators

  • Eman Baraka, MD · Assisstant Profesoor

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2020-11-20
Completion
2020-12-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04467450 on ClinicalTrials.gov